Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.29 +0.01 (+0.02%)
Streaming Delayed Price Updated: 1:24 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
31 32 Next >
Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact
Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each... 
Via Benzinga
Sanofi Expects Moderate 2023 Profit Growth On Dupixent Demand, But Dampened By Aubagio Generics Competition
Via Benzinga
Alphabet, Apple And 3 Stocks To Watch Heading Into Friday
With Nasdaq stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Fear & Greed Index Remains In 'Greed' Zone As Nasdaq Record Sharp Gains For Fourth Straight Week
The CNN Money Fear and Greed index showed some decline in overall sentiment among US investors. US stocks closed mostly higher on Thursday, with the tech-laden Nasdaq index leading the rally. Investors... 
Via Benzinga
Earnings Outlook For Sanofi
Via Benzinga
Hopeful Golden Cross Forms On Sanofi's Chart
Via Benzinga
What Does Sanofi's Debt Look Like?
Over the past three months, shares of Sanofi Inc. (NASDAQ:SNY) increased by 20.92%. Before having a look at the importance of debt, let's look at how much debt Sanofi has. 
Via Benzinga
Sanofi Forecasts Foreign Exchange, Record Flu Vaccine Sales To Boost Q4 Earnings
Via Benzinga
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
Sanofi Layoffs 2023: What to Know About the Latest SNY Job Cuts
One French pharmaceutical producer is implementing job cuts. Here's what investors need to know about the Sanofi layoffs. 
Via InvestorPlace
Sanofi Might Pull Down Shutters For Two Vaccine Plants In India
After Sanofi SA (NASDAQ: SNY) failed to secure a UNICEF contract, the company is weighing closing operations at two of its vaccine-making facilities in Hyderabad, India, and plans to let go of all... 
Via Benzinga
Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis
Via Benzinga
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed. 
Via Benzinga
Could This Vaccine Become Sanofi's Latest Blockbuster?
This vaccine candidate could be approved in newborns and infants later this year. 
Via The Motley Fool
7 Blue-Chip Stocks to Buy as a New Bull Market Emerges
Many blue-chip stocks look like a bargain right now, and these seven companies are certainly no exception. 
Via InvestorPlace
Mergers and Acquisitions in 2023 Off To A Strong Start
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road. 
Via MarketBeat
Exposures Product Safety
Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023
It's difficult to imagine a future where healthcare isn't in high demand. 
Via The Motley Fool
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
After years of lab failures, the companies could crack open a multibillion-dollar market. 
Via Investor's Business Daily
The Viral “Tripledemic” Opportunity
Between Covid, the flu, and RSV, investors in over-the-counter consumer pharmaceutical companies might be wondering if now is a logical time to up their holdings in the companies that make cold and flu... 
Via Talk Markets
Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot
Johnson & Johnson (NYSE: JNJ) has significantly scaled back its efforts of manufacturing its COVID-19 vaccine after facing a fall in demand. 
Via Benzinga
Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics
Via Benzinga
What This Drug News Could Mean for Sanofi Shareholders
This star drug for Sanofi is one step closer to approval in the European Union for another chronic inflammatory disease. 
Via The Motley Fool
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
The biggest drug company blockbusters bring in billions of dollars, which is one of the reasons to consider these top Pharma stocks. 
Via InvestorPlace
FDA Permits Pharmacies To Distribute Abortion Pills, Tesla's Aggressive Discounting May Have Hit Gross Margins, Goldman Sachs Bullish On M&A Activity In Late 2023: Top Stories Today
Reuters Goldman Sachs Bullish On M&A Deals Activity Picking Up In Late 2023 
Via Benzinga
Could This Drug News Give a Lift to Eli Lilly Stock?
In November, Eli Lilly received positive news from the U.S. Food and Drug Administration. 
Via The Motley Fool
3 Medical Dividend Stocks That Hit the Sweet Spot
These three offer high dividend yields and consistent revenue growth. 
Via The Motley Fool
After Five Years Of Collaboration, Sanofi & Innate Pharma Expand Oncology Pact With Additional Programs
Via Benzinga
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology
From Innate Pharma SA
Via Business Wire
Market Rally Pressured On Fed Rate Outlook; Moderna, Boeing, Tesla In Focus: Weekly Review
Moderna spiked on a cancer vaccine while Tesla continued to dive. 
Via Investor's Business Daily
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.